List of Tyzeka drug patents
Tyzeka is owned by Novartis.
Tyzeka contains Telbivudine.
Tyzeka has a total of 2 drug patents out of which 0 drug patents have expired.
Tyzeka was authorised for market use on 28 April, 2009.
Tyzeka is available in solution;oral dosage forms.
Tyzeka can be used as treatment of chronic hepatitis b in adult patients.
The generics of Tyzeka are possible to be released after 11 September, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7858594 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(7 months from now) | |
| US7589079 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(7 months from now) | |
Drugs and Companies using TELBIVUDINE ingredient
Market Authorisation Date: 28 April, 2009
Treatment: Treatment of chronic hepatitis b in adult patients
Dosage: SOLUTION;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic